Bringing Healthcare to Life

Inspiring Innovation. Expanding Care.

For over 45 years, Steve Gorlin has been building companies primarily in the biotech and pharma industries. He invests and works with the founders & innovators setting up management, building the operations and bringing in blue chip investors. Mr. Gorlin, with his leadership team, has developed a proprietary methodology for start-up companies, which ensures company success by increasing its market value and creating a high rate of return for investors through an exit via an IPO or private sale.

Gorlin Companies is a healthcare focused Single Family Office specializing in building innovative companies that improve patient quality of care and healthcare economics globally. The company invests across the biotech and pharma sectors at all stages of development, with an emphasis on U.S. based companies that have immediate potential in international markets.

Gorlin Companies has the participation of a wide range of experts in both healthcare and venture investing. Drawing from deal sourcing, legal, fund raising, operational, and due diligence experiences across the healthcare landscape, Gorlin Companies has created a style and a proven track record of investments with high growth potential.

Performance

Biotech/Pharma companies

1981
1986
1988
1990
1996
2004
2005
2007
2011
1981

1981

HYCOR - Monoclonal Antibodies. Founded with Dr. Paul Price and Dr. David Gordon who at the time, were co-directors of the Hybridoma Lab at the Centers for the Disease Control & Prevention (CDC). Gorlin financed company prior to $6 million IPO. Second Monoclonal company to go public.  Sold to Agilent for $100 million. Currently, subsidiary of Agilent.
1986

1986

THERAGENICS -Palladium implants for prostate cancer. Founded with Dr. John Russell, director of the Frank Neely Nuclear Research Center at Georgia Tech. Initially a privately financed company. Performed a reverse merger into a public shell value of $6 million. Managed from inception through sale. Reached market value of over $1 billion during Gorlin's involvement. NYSE: TGX
1988

1988

CytRx -Products to increase blood flow and dissolve clots for heart attacks and other blood vessel issues. Technology licensed from Emory University. Gorlin invested $200,000, raised additional funds and then took it public. The first IPO was $6 million. During Gorlin’s leadership, the company reached a market cap of over $200 million. NASDAQ: CYTR
1990

1990

MEDICIS -Dermatology.  The company was started with Gorlin's FDA attorney, Jonah Shacknai. It  began as an idea funded by Gorlin. Sold to Valeant Pharmaceuticals for $2.68 billion. The company is currently a subsidiary of Valeant.
1996

1996

EntreMed -Licensed anti-angiogenesis technology. This Technology was developed by Dr. Judah Folkman from Harvard Children’s Hospital. Reached a $1.4 billion market cap during involvement as Chairman. Sold to Casi Pharmaceuticals.
2004

2004

MEDIVATION -Drugs for refractory prostate cancer. Founded with Dr. David Hung. Gorlin loaned the money to start the company and took it public. The company was sold to Pfizer for $14 billion. NASDAQ: MDVN
2005

2005

MRI INTERVENTIONS -Platforms for minimally invasive surgical procedures in the brain and heart. Worked with Dr. Ali Rezhai of the Cleveland Clinic. Started the company and took it public. NASDAQ: MRIC
2007

2007

MiMedx - Innovative bioactive healing products for tissue regeneration. Founded the company. Is currently public with a market cap of $1.06 billion. NASDAQ: MDXG.
2011

2011

DARA Biosciences -Treatment for neuropathic pain and cancer. Mr. Gorlin started the company and invested $800,000 of Dara’s money in Medivation. He then distributed over half of Medivation's shares to Dara shareholders. Recently sold to Midatech Pharma.

Other companies

1990
1991
2001
2009
1990

1990

PermaFix -Environmental cleanup of nuclear waste. Gorlin started the company. Gorlin sold his interest when the company was valued in excess of $100 million. NASDAQ: PEFI

1991

Pretty Good Privacy Business encryption software. Worked with son and Phil Zimmerman and raised all of the funding. Two years after founding, sold to Network Associates, Inc. for $38 million. Network Associates sold to Symantec in 2010.
2001

2001

Judicial Correction Services -Private probation services. Helped son start the company; raised the initial funds. Sold to Correctional Healthcare for a return to investors of 3-5 times their initial investment. In 2014 it was acquired by Correct Care, LLC.
2009

2009

Kabbage -Loans for small businesses.  Mr. Gorlin assisted his son, Marc Gorlin, in starting the company. Currently, the company loans over $1 billion a year and is valued by major investment banks at $800 million to $1 billion.

Collaborators

David Bonderman is an American businessman and philanthropist. He is the founding partner of TPG Capital and its Asian affiliate, Newbridge Capital and has served on numerous Boards of Directors. Full profile

David Bonderman
David Bonderman Founding Partner, TPG Capital

G. Donald Johnson, JD is a corporate transactions attorney with more than three decades of experience guiding clients in M&A transactions, as well as public and private equity financing. Full Profile

G. Donald Johnson
G. Donal Johnson, JD Founding Member, Womble & Carlysle

Chris Marlett is CEO and Founder of MDB Capital Group LLC. His entire 26 year career has been focused on financing emerging growth companies in the public markets. Full Profile

Chris Marlett
Chris Marlett CEO & Founder, MDB Capital Group

Len Potter serves as President and Chief Investment Officer of Wildcat Capital Management, LLC, a registered investment advisor, he founded in 2011. He serves on the boards of directors of Solar Senior Capital, Ltd. (SUNS), Solar Capital Ltd. (SLRC), GSV Capital Corp. (GSVC), ViCapsys, Stonegate Production Company and Auto Europe Groupinvestor. Full Profile

Len Potter
Lenn Potter President and Chief Investment Officer, Wildcat Capital Management

John W. S. Preston has over 30 years of successful shopping center development and investment experience throughout North America. He was the founder of the North American Development Group of Companies, which is one of the largest private developers of retail shopping centers in North America. Full Profile

John Preston
John Preston Founder, North American development Group

Burke Ross has 40 years of extensive experience in private equity investing. Currently Mr. Ross serves as the Chairman of the Investment Committee at Palm Beach Capital investor. Full Profile

E. Burke Ross Chairman of the Investment Committee, Palm Beach Capital investor

Patrick Soon-Shiong, MD is a doctor, philanthropist and entrepreneur who founded two drug companies, invented a blockbuster cancer drug and is currently building his NantWorks health empire. He has donated more than $130 million to health care improvement and plans to give away at least half his fortune. Full profile

Patrick Soon-Shiong
Patrick Soon-Shiong, MD Physician, Inventor, Scientist

Contact Us

Alpine Bank Building. 600 E. Hopkins Ave., #302. Aspen CO 81611
agardner@gorlincompanies.com

to top button